Rationale and Design for a Multicenter, Phase II Study of Durvalumab Plus Concurrent Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Study (WJOG11619L)

Durvalumab (anti-programmed cell death ligand-1) administration after concurrent chemoradiotherapy (cCRT) has improved the survival of patients with unresectable, locally advanced (LA) stage III non-small cell lung cancer (NSCLC). Some patients are unable to complete cCRT and cannot receive immunoth...

Descripción completa

Detalles Bibliográficos
Autores principales: Tachihara, Motoko, Tsujino, Kayoko, Ishihara, Takeaki, Hayashi, Hidetoshi, Sato, Yuki, Kurata, Takayasu, Sugawara, Shunichi, Okamoto, Isamu, Teraoka, Shunsuke, Azuma, Koichi, Daga, Haruko, Yamaguchi, Masafumi, Kodaira, Takeshi, Satouchi, Miyako, Shimokawa, Mototsugu, Yamamoto, Nobuyuki, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684372/
https://www.ncbi.nlm.nih.gov/pubmed/34934361
http://dx.doi.org/10.2147/CMAR.S336262

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684372/
https://www.ncbi.nlm.nih.gov/pubmed/34934361
http://dx.doi.org/10.2147/CMAR.S336262

Ejemplares similares